FMF World Congress 2023: Janssen shares new data in HDFN
If approved, nipocalimab would be the first anti-FcRn therapy for EU pregnancies at high risk of haemolytic disease of the foetus and newborn.
List view / Grid view
If approved, nipocalimab would be the first anti-FcRn therapy for EU pregnancies at high risk of haemolytic disease of the foetus and newborn.
Martin Vogel, Therapeutic Area Lead for Oncology, Janssen EMEA, discusses the potential of bispecific monoclonal antibodies like amivantamab to address unmet needs in advanced non-small cell lung cancer treatment.
17 May 2017 | By Dr Catherine Taylor, Haematology Therapeutic Area Lead, Janssen EMEA
We caught up with Janssen's Dr Catherine Taylor to talk monoclonal antibodies, the rise of immuno-oncology and treating multiple myeloma...
1 June 2016 | By Victoria White, Digital Content Producer
The EC has approved the use of Trevicta (paliperidone palmitate a 3-monthly injection) for the maintenance treatment of schizophrenia in adult patients...
5 April 2016 | By Victoria White
If approved, this 3‑monthly injection will allow patients to maintain an optimal level of treatment in their blood with fewer administrations...
26 October 2015 | By Victoria White
If approved by the European Commission, Edurant will become available for the treatment of adolescents with HIV-1 for the first time...
16 September 2015 | By Victoria White
Blue Latitude has been reappointed to provide Janssen with strategic support and creative marketing services for their brand teams in the EMEA region...
10 September 2015 | By Victoria White
Daratumumab is an investigational, human anti-CD38 monoclonal antibody, for the treatment of patients with relapsed and refractory multiple myeloma...
3 July 2015 | By Victoria White
The EC has approved Janssen’s Stelara for the treatment of moderate-to-severe plaque psoriasis in adolescent patients from the age of 12 years and older...
27 May 2015 | By Victoria White
The CHMP has recommended approval of STELARA for the treatment of moderate to severe plaque psoriasis in adolescent patients aged 12 and older...
24 March 2015 | By Victoria White
Janssen Health Policy Centre (Janssen Pharmaceutica NV) today unveiled the EU Disease Lens: a digital dashboard that brings insight into 15 major diseases...
10 October 2014 | By Janssen
Persistence of STELARA® (ustekinumab) significantly better than Anti-TNFs in treatment of Psoriasis according to observational study analysis...
7 June 2012 | By Publicis Life Brands Resolute
New efficacy and safety data...